‘Safety Switch’ Proposed for Cell Therapies – MedPage Today

The front runner has been modifying cells with herpes simplex virus type 1 thymidine kinase (HSVtk) that can be activated with acyclovir (Zovirax) or ganciclovir (Cytovene). However, moving away from HSVtk to strategies such as iCaps9 would allow those …